KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
KRMD
Repro Med Systems IncNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$155.14M
P/E Ratio
—
EPS
$-0.04
Beta
0.45
52W High
$6.61
52W Low
$3.21
50-Day MA
$4.03
200-Day MA
$4.57
Dividend Yield
—
Profit Margin
-4.03%
Forward P/E
188.68
PEG Ratio
—
About Repro Med Systems Inc
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.
Fundamentals
| Revenue (TTM) | $45.11M |
| Gross Profit (TTM) | $28.16M |
| EBITDA | -979,396 |
| Operating Margin | 5.21% |
| Return on Equity | -10.50% |
| Return on Assets | -3.86% |
| Revenue/Share (TTM) | $0.97 |
| Book Value | $0.39 |
| Price-to-Book | 8.70 |
| Price-to-Sales (TTM) | 3.42 |
| EV/Revenue | 3.37 |
| EV/EBITDA | -17.15 |
| Quarterly Earnings Growth (YoY) | -66.00% |
| Quarterly Revenue Growth (YoY) | 18.20% |
| Shares Outstanding | $46.17M |
| Float | $34.48M |
| % Insiders | 8.10% |
| % Institutions | 56.45% |
Historical Volatility
HV 10-Day
78.85%
HV 20-Day
68.08%
HV 30-Day
57.64%
HV 60-Day
52.63%
HV Rank
75.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.60 target)
4
Buy1
HoldLatest News
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
Business Wire8/5/2026Neutral
KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026. KORU Medical's management is scheduled to present at the Canaccord Genuity 46th Annual.
Business Wire7/29/2026Neutral
Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company's current shareholders.The investigation seeks to determine whether KORU and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.KORU shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information abo.
Business Wire7/22/2026Neutral
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.
Business Wire7/15/2026Neutral
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nur.
Business Wire5/18/2026Neutral
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
Seeking Alpha5/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KRMD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026